Previous randomized controlled trials (RCTs) have demonstrated the cardioprotective benefits of SGLT2 inhibitors on HF (figure 3).7, 9 Recently, several MR studies were conducted to explore the molecular mechanisms involved. Here, SLC5A2 is linked to hydrops fetalis.